420 related articles for article (PubMed ID: 12462297)
1. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
2. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Palmer AJ; Roze S; Lammert M; Valentine WJ; Minshall ME; Nicklasson L; Gall MA; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
[TBL] [Abstract][Full Text] [Related]
3. Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States.
Caro JJ; Salas M; O'Brien JA; Ishak K; Sung J; Raggio G
Value Health; 2004; 7(1):13-21. PubMed ID: 14720127
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
7. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
8. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Israel MK; Istvan E; Baron MA
Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Weaver JU; Robertson D; Atkin SL
Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
12. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
[TBL] [Abstract][Full Text] [Related]
16. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Gerich J; Raskin P; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
[TBL] [Abstract][Full Text] [Related]
18. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
20. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Baron MA
Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
[No Abstract] [Full Text] [Related]
[Next] [New Search]